DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clonidine to Prevent Implantable Cardiovertor Defibrillator Firing

Information source: University of Iowa
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ventricular Tachycardia

Intervention: clonidine (Drug); metoprolol (Drug)

Phase: N/A

Status: Terminated

Sponsored by: University of Iowa

Official(s) and/or principal investigator(s):
james b martins, md, Principal Investigator, Affiliation: University of Iowa


Cardiac arrest or sustained VT (ventricular tachycardia) in patients with heart disease is best treated with an ICD (implantable cardioverter defibrillator). However, the ICD alone is not appropriate therapy for patients with frequent VT episodes. In fact frequent shocks for VT may predict a poorer prognosis. Anti-arrhythmic drugs are co-administered with ICDs in up to 50% of patients to prevent VT episodes, but antiarrhythmic drugs may have harmful effects. Thus improved drugs to prevent VT without interfering with ICD function are needed. Recent data including our own suggest that clonidine may be a new therapy to prevent ICD shocks. It may act centrally on sympathetic outflow and peripherally and selectively on cardiac Purkinje, to suppress and control VT occurring in patients. Our purpose is to test the hypothesis that clonidine reduces frequent VT better than beta blocker in patients with ICDs. After informed consent patients will be randomized in a single blind fashion to either clonidine or metoprolol given three times per day. Other prescribed drugs may be adjusted to promote toleration of the study drug. ICD interrogations of episodes of VT will be the primary endpoint. Device based NIPS (non-invasive programmed stimulation) testing in a subset of these patients will allow mechanistic understanding of the clonidine effect. All of the procedural techniques are in place as performed clinically; preliminary data are given showing feasibility of the project.

Clinical Details

Official title: Clonidine to Prevent Implantable Cardiovertor Defibrillator Firing

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: episodes of non-sustained ventricular tachycardia

Secondary outcome: defibrillator shocks

Detailed description: we had wanted very commonly occurring VT episodes on ICD interrogation: 5 episodes/ 3months. We could not enroll more than 8 patients most of which have interventions to prevent episodes. Thus we could not enroll patients and discontinued the study in the first year.


Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.


Inclusion Criteria:

- Implantable defibrillator treated patients with 5 episodes of ventricular tachycardia

per 3 month period Exclusion Criteria:

- No more than one shock/3 months

- No contraindication to clonidine

- Non-compliance

- Asthma

Locations and Contacts

UIHC, Iowa City, Iowa 52242, United States
Additional Information

Starting date: May 2006
Last updated: December 9, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017